{"id":"W4391884527","doi":"10.1158/2767-9764.crc-22-0516","title":"CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma","year":2024,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"Hepatitis C virus research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Chugai Pharmaceutical; Stand Up To Cancer; Genentech; Ipsen; Servier; Eisai; Incyte; Astex Pharmaceuticals; Novocure; Sanofi; Exelixis; BioClinica; Regeneron Pharmaceuticals; National Institutes of Health; Helsinn; Gilead Sciences; Celgene; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Sorafenib; Hepatocellular carcinoma; Medicine; Hepatitis C virus; Internal medicine; Hepatitis C; Titer; Gastroenterology; Hepacivirus; Discontinuation; Immunology; Oncology; Virus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00123832,0.000491843,0.00130929,0.00028002,0.0002371613,0.0005625437,0.0003635388,0.0005325708,0.001612671],"category_scores_gemma":[0.001587378,0.000207563,0.001015372,0.0003453064,0.0003391228,0.0006301062,0.000409136,0.001200011,0.0002263998],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008437591,"about_ca_system_score_gemma":0.001084298,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003056115,"about_ca_topic_score_gemma":0.009002565,"domain_scores_codex":[0.999621,0.0001827555,0.00002792899,0.00006363139,0.0000448445,0.00005984181],"domain_scores_gemma":[0.999463,0.000115077,0.0001262859,0.00003053333,0.00003922203,0.0002259212],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6821889,0.008229419,0.06231565,0.001057096,0.003161648,0.0001662735,0.0001214396,0.001995645,0.008324496,0.0002432002,0.004111442,0.2280848],"study_design_scores_gemma":[0.3439173,0.1732945,0.4660775,0.0002260928,0.004435499,0.0004986012,0.0001805413,0.00398538,0.001519504,0.0004076621,0.00537323,0.00008414496],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932822,0.004499346,0.00007436587,0.0005154163,0.0000853669,0.0001356809,0.0002596909,0.00002335665,0.001124489],"genre_scores_gemma":[0.9960213,0.001829521,0.0002168037,0.0004347658,0.00009589244,0.0001013213,0.000717637,0.000004837525,0.0005778908],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003056115,"threshold_uncertainty_score":0.006548941,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07582060412169538,"score_gpt":0.4308331225200983,"score_spread":0.3550125183984029,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}